the risk of thrombotic events in patients with mgus: an analysis from the istopmm trial
Published 6 months ago • 90 plays • Length 3:26Download video MP4
Download video MP3
Similar videos
-
1:21
trends in allosct for good-risk aml: a longitudinal study
-
1:34
are thrombotic risk and progression in et predictable?
-
2:31
updates in the diagnosis, risk stratification & treatment of aml: who, icc, and eln classifications
-
6:45
novel scoring system defines allo-hsct patients at high risk for cmv
-
6:31
a meta-analysis assessing the safety of cytoreductive therapies in younger patients with pv
-
1:32
factors contributing to the pathogenesis of icaht
-
9:25
mgus diagnosis: a step-by-step approach
-
40:35
the orac assay: industrial and academic relevance
-
30:38
correlation of multiplex immunofluorescence with rna sequencing | zhongmin xiang, phd | bostongene
-
2:00
the potential use of molecular response as a surrogate marker for survival outcomes in mpns
-
1:24
triple-negative myelofibrosis: disease features and outcomes
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
1:05
risk-factors for richter’s transformation
-
1:29
updates on the diagnosis, risk stratification and management of hl
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
2:20
ultra high-risk myeloma
-
3:24
prefibrotic myelofibrosis: considerations for diagnosing and managing this entity
-
5:00
long-term results of the phase ii revive study evaluating rusfertide in patients with pv
-
1:09
the changing role of allosct in dlbcl in the era of novel agents
-
8:40
lenalidomide, mutations & mds outcomes
-
1:55
diagnosing and treating aml: the role of mutational profiling